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Abstract
Background: Radiotherapy is of critical importance in the treatment of breast cancer. However, not all patients
derive therapeutic benefit and some breast cancers are resistant to the treatment, and are thus evidenced with
prospective distant metastatic spread and local recurrence. In this study, we investigated the potential therapeutic
effects of all-trans retinoic acid (ATRA) on radiation-resistant breast cancer cells and the associated invasiveness.
Methods: The MCF7/C6 cells with gained radiation resistance after a long term treatment with fractionated ionizing
radiation were derived from human breast cancer MCF7 cell line, and are enriched with cells expressing putative
breast cancer stem cell biomarker CD44+/CD24-/low/ALDH+. The enhanced invasiveness and the acquired resistances
to chemotherapeutic treatments of MCF7/C6 cells were measured, and potential effects of all-trans retinoic acid
(ATRA) on the induction of differentiation, invasion and migration, and on the sensitivities to chemotherapies in
MCF7/C6 cells were investigated.
Results: MCF7/C6 cells are with enrichment of cancer stem-cell like cells with positive staining of CD44+/CD24-/low,
OCT3/4 and NANOG. MCF7/C6 cells showed an increased tumoregensis potential and enhanced aggressiveness
of invasion and migration. Treatment with ATRA induces the differentiation in MCF7/C6 cells, resulting in reduced
invasiveness and migration, and increased sensitivity to Epirubincin treatment.
Conclusion: Our study suggests a potential clinic impact for ATRA as a chemotherapeutic agent for treatment of
therapy-resistant breast cancer especially for the metastatic lesions. The study also provides a rationale for ATRA as
a sensitizer of Epirubincin, a first-line treatment option for breast cancer patients.
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Background
Breast cancer is the leading cancer diagnosed in
women and is second only to lung cancer in terms of
cancer death, causing extensive morbidity and psycho-
logical distress to millions globally [1, 2]. Despite the
tremendous efforts and progress in breast cancer re-
search and early diagnosis, clinical outcome for breast
cancer patients is still disappointing. Resistances to
current therapeutic regimen, and as much as 40 % of
relapses with recurrent and/or metastatic disease
remain to be great challenges in clinical management
for breast cancer patients [3–5]. It is also needed to
be indicated that, while overall breast cancer mortality
rates have decreased over the last several decades [6],
the survival rates for metastatic breast cancer are
currently estimated at less than 25 % for 5-year and
5–10 % for 10-year [3, 7–9].
Radiation therapy continues to be an important part of
conditioning regimens for breast cancer treatment. Radi-
ation therapy given after surgery in early stage breast
cancer patients has shown significant effects of increas-
ing the probability of both local control and survival
[10]. The most recent meta-analysis including 10,801
women in 17 clinical trials of radiation or no radiation
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after lumpectomy showed that radiation reduced the 10-
year risk of any recurrence in lymph node-negative
women from 31 to 15.6 % and reduced the 15-year risk
of death from breast cancer from 20.5 to 17.2 % [11].
However, the rate of totally control of tumor growth by
radiotherapy remains unacceptable low, and studies
have indicated that breast cancer patients may fail to
radiation therapy and cancer cells in these patients
become resistant to the treatment [12–15]. Elucida-
tion of mechanism causing tumor radioresistance and
definition of effective therapeutic targets to enhance
tumor response, especially for the most resistant and
aggressive cancer cells in the recurrent and metastatic
lesions, are thus urgently needed.
In our previous studies, we observed a breast cancer
MCF7 cell population (MCF + FIR) that could survive
after a course of clinical fractionated doses of radiation
and showed enhanced radioresistance compared to the
wild type parental MCF7 cells [16, 17]. With sub-
cloning, different clones with varied radiosensitivity were
isolated from this radioresistant population [18]. Cells
expressing the biomarkers of breast cancer stem cells
(BCSCs; e,g., CD44+/CD24-/low/ALDH+) were further
sorted and confirmed in one of these clones (MCF7/C6)
[19], indicating that BCSCs can survive long-term
fractionated radiation and be responsible tumor repopu-
lation with radiation resistance. In supporting this obser-
vation, other studies also demonstrated the enrichment
of cancer stem cells during the course of fractionated ra-
diation [20, 21]. In addition, radiation is also shown to
be able to reprogram the differentiated breast cancer
cells into induced breast cancer stem cells (BCSCs) [22].
These and other results provide the evidence indicating
that, while some patients with early-stage breast cancer
can benefit from radiation therapy, others may gain re-
sistance to radiotherapy with a potential of increased
recurrence and/or distant metastasis due to the enrich-
ment of BCSCs [23]. Thus, targeting BCSCs in patients
with radiation resistant breast cancer may impede an im-
portant clinical impact for decreasing cancer metastatic
potential in these patients.
In this study, we used the MCF + FIR cellular model to
investigate the roles of BCSCs in enhanced capability of
cancer cell invasion and the acquired resistances to
chemotherapy of breast cancer. The potential thera-
peutic effects of all-trans retinoic acid (ATRA), which
has been used in the management of certain hematologic
malignancies and solid tumors, including breast cancer
[24], on the induction of differentiation of enriched
BCSCS, inhibition of aggressive growth and sensitization
to chemotherapeutic agent in MCF/C6 cells. The re-
sults indicate that ATRA is a promising candidate to




ATRA was purchased from Sigma–Aldrich (St. Louis,
MO), and was dissolved in dimethylsulphoxide (DMSO)
as stock solution. Primary antibodies for Involucrin,
Sydencan-3, and E-Cadherin were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-CD44 anti-
body was from ABGENT (San Diego, CA). Anti-β-actin
antibody was from Cell Signaling Technology (Beverly,
MA). siRNA oligos for CD44 and control siRNA-A were
also from Santa Cruz Biotech. Inc. Enzymes I-SceI was
from New England Biolabs (Ipswich, MA).
Cell culture
Human breast cancer MCF7 cells were from American
Type Culture Collection (ATCC, Manassas, VA). Radiation-
resistant MCF7/C6 cells were generated from MCF-7 cells
by exposure to fractionized ionizing irradiation (FIR) with a
total dose of 60 Gy of γ-irradiation (2 Gy per fraction, five
times per week for 6 weeks) as previously described [17].
MCF7 and MCF7/C6 cells were maintained in ATCC-
formulated RPMI-1640 medium supplemented with 10 %
Fetal bovine serum (FBS), 5 % sodium pyruvate, 5 % nones-
sential amino acid, 100 U/mL of penicillin, and 100 mg/mL
streptomycin in a 37 °C incubator (5 % CO2). To maintain
the radiation-resistant phenotype, MCF7/C6 cells were also
frequently exposed to irradiation (IR) at 2Gy for five times
per week and radioresistance was validated before each des-
ignated experiment.
Clonogenic survival assay
Cells in log-phase were plated and then immediately
treated with indicated treatment. 24 h later, cells were
washed twice with pre-warmed medium, and were then
maintained in corresponding medium for 10–14 days
and stained with crystal violet. Colonies consisting >50
cells were considered as survival colonies and directly
scored using an inverted microscope. Average numbers
for survival colonies were plotted versus untreated con-
trol to determine the survival fractions. When ATRA
pretreatment applied, cells were treated 10 μM ATRA
for 72 h. Cells were then re-plated and treated with
indicated chemodrugs for 24 h, and maintained in
corresponding medium for colony formations as de-
scribed above.
Assays for invasion, migration and wound healing
MCF7 and MCF7/C6 cells in log-phase were trypsinized,
and 5 × 104 cells in growth medium containing 1 % FBS
were re-seeded in 1× BME (Trevigen, Gaithersburg,
MD) coated 8.0-μm pore size cell culture inserts (for 24-
well plate, Millipore, Danvers, MA). Complete growth
medium containing 10 % FBS was placed outside the
chambers, and cells were allowed to invade toward the
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attractant of full-serum medium. Chamber filter process-
ing and visualization/quantitation of invasion were per-
formed, as previously described [25]. Cells migrated to
bottom chamber were also visualized/quantified for
migration analysis.
For wound healing analysis, 5 × 104 cells were grown
in monolayers in triplicate in 24-well plates for 72 h.
The confluent monolayer was then scraped with a sterile
tip. The migration into the wounded monolayer was
assessed by microscopy. When siRNA transfection ap-
plied, cells were transiently transfected with SiRNA-
CD44 or SiRNA-Control-A, and then maintained in
complete medium for 72 h until confluent monolayer
formed for wound healing analysis, or re-seeded in
BME-precoated cell culture inserts for invasion/migra-
tion assays.
Flow cytometry analysis
After treatments, cells were detached by using stem-
pro® accutase (Life Technologies, Grand Island, NY),
and washed twice with PBS. Cells were then stained
with PE-conjugated anti-Sox2, anti-Oct3/4, and anti-
NANOG antibodies, or co-stained with PE-conjugated
anti-CD24 and FITC-conjugated anti-CD44 antibodies
(BD Biosciences, San Jose, CA). In the process for
staining of Sox 2, Oct3/4 and Nanog, BD Perm/
WashTM buffer was also used per manufacture’s in-
struction. PE- or FITC-positive cells were quantified
by flow cytometric analysis on Flow Cytometer LSRII
(BD Biosciences, San Jose, CA). Up to 5 × 104 cells
were counted during flow cytometry analysis. For cell
cycle analysis, cells were collected and fixed with
75 % ethanol, stained with propidium iodide and ana-
lyzed by flow cytometry with 5 × 104 events counting
per run, as described previously [26]. The percentage
of cells in the G1, S, and G2/M phases of the cell
cycle were determined by using Flowjo software
(Flowjo data analysis software, OR).
Immunoblot assay
Cell lysates were prepared in RIPA buffer with mild son-
ication, and subjected to SDS-PAGE gel for immunoblot
assays. β-actin was included to determine equivalent
protein loading.
in vivo end-joining assay
in vivo end-joining assay was based on the reactivation
of linearized plasmid as previously reported [27]. Briefly,
cells were treated with 10 μM of ATRA, or DMSO as
control, for 72 h, 1 × 105 cells were then co-transfected
with 1.2 μg linearized EJ5-GFP substrates (linearized
with I-SceI) and 0.5 μg circular pDsReD-Express2-N1
(as transfection control) by using electroporation
(Gene Pulse Xcell, Bio-Rad, Hercules, CA). After
transfection, cells were plated and cultured in fresh
complete medium for 72 h. In ATRA experiment,
10 μM ATRA was added into culture medium after
transfections and DMSO was included as control.
Flow cytometry analysis was performed with Fortessa
Flow Cytometer (Fluofarma, Princeton, NJ). Up to 5 × 104
cells were counted. The ratio of GFP-positive cells to
DsRed-positive cells was used as a measure of end-
joining efficiencies.
Tumor initiating test
Tumor initiating test was conducted following the de-
scribed methods [19, 28] and the protocol was reviewed
and approved by the Chancellor’s Animal Research
Committee (ARC) at the University of California Los
Angeles (ARC #2009–063–13). Six weeks old female
NOD/SCID mice (Jackson Lab, Bar Harbor, ME) were
pretreated for 5 days with estrogen pellets (Innovative
Research of America, Sarasota FL) and freshly prepared
MCF7 and MCF7/C6 cells were resuspended in serum-
free PBS/Matrigel mixture (1:1 V/V), and 1×103 cells
were inoculated subcutaneously to bilateral franks of
same animal. Tumorigenesis was assessed twice a week
with palpation. Tumor sizes were determined from cali-
per measurements of tumor length (L) and width (W)
according to the formula (LxW2)/2.
Statistical analyses
Statistical analyses were performed using the Student’s
t-test. A p value <0.05 was considered as significant (*).
Results
Enhanced cancer cell invasiveness and migration of
radiation-resistant MCF7/C6 cells
Radiation in cancer treatment is intended to destroy
cancer cells by damaging their DNA, and the resistance
of cells to IR is thus modulated by three intimately re-
lated cellular processes, including DNA damage repair
[29]. In this study, we first verified the radioresistance of
MCF7/C6 cells. We found that the clonogenic survival
rate was enhanced in MCF7/C6 cells to about 12-fold
when compared to that of wild type MCF7 cells
(Fig. 1a). Using in vivo end-joining assay, we detected
the DNA repair capacity in MCF7/C6 versus wild
type MCF7 cells and the results showed that NHEJ
(non-homologous end-joining) DNA repair efficiency
was about two-folds in MCF7/C6 cells compared to
the wild type MCF7 cells (Fig. 1b). In agreement with
NHEJ being an indicator of intrinsic DNA damage re-
pair capacity [29, 30], these results indicate that DNA
repair cacapicity plays a role in signaling the radiore-
sistant phenotype of MCF7/C6 cells.
It has been previously shown that HER2-positive
cells in MCF7/C6 were with increased invasiveness
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[19]. In an attempt to test whether MCF7/C6 cells
have overall changes in cancer cell invasiveness and
migration, we performed the assays in MCF7 and
MCF7/C6 cells. We observed that the capabilities of
cancer cell invasion/migration were dramatically en-
hanced in MCF7/C6 cells versus parental MCF7 cells.
MCF7/C6 cells also showed increased ability for
wound healing (Fig. 1c, d). In addition, a substantial
amount of E-cadherin, a protein prominently associ-
ated with tumor invasiveness and metastatic dissemin-
ation [31], was found to be reduced in the MCF7/C6
cells (Fig. 1e).
Enrichment of stem cell-like cancer cells in MCF7/C6 cells
We next examined the potential enrichment of stem
cell-like cancer cells, or cancer stem cells (CSCs), in
MCF7/C6 cells. Our previous study has revealed the en-
richment of HER2+/CD44+/CD24-/low cancer stem cell
population in MCF7/C6 cells. In this study, we used can-
cer stem cell surface marker CD44+/CD24-/low, a first
described marker for BCSCs [32, 33], and embryonic
stem cell markers Oct3/4 [34], Sox II [35] and Nanog
[36] to determine the putative cancer stem cells. Flow
cytometry analyses showed significant increases of cell
populations with positive staining of CD44+/CD24-/low
(from 1.26 ± 0.52 to 35.8 ± 3.41), Oct3/4 (2.78 ± 0.87 to
23.7 ± 4.66) and Nanog (from 47.6 ± 2.33 to 74.1 ± 4.27)
in MCF7/C6 cells (Fig. 2a, c). In addition, we also de-
tected increase of CD44-positive population, a determin-
ant cell membrane protein in cell migration and
invasion [37], in MCF7/C6 cells, which was further con-
firmed by western blot analysis (Fig. 2b, c). In NOD/
SCID mouse, we found that all the sites inoculated with
MCF7/C6 cells (1000 cells/injection) developed tumors
(4/4) with an average volume of 259 mm3 at day 35;
whereas three of four sites inoculated with the same
number of MCF7 cells showed detectable tumors with
an average volume of 20 mm3 (Fig. 2d and Additional
file 1: Figure S1). MCF7/C6 cells also showed shorter
latency for forming tumors when compared to MCF7
cells (16 ± 5 days versus 26 ± 2 days). Thus, the results of
tumor initiating test suggested that radioresistant
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Fig. 1 Radiation-resistant MCF7/C6 cells are more invasive cancer cells. a Increased radioresistance measured by clonogenic survivals of MCF7
and MCF7/C6 cells. b NHEJ efficiency measured by in vivo EJ assay. Cells were co-transfected with linearized EJ5-GFP plasmid and control pDsRed,
and were then treated with 2 Gy of IR. Re-circulated EJ5-GFP was counted by flow cytometry analysis 72 h after transfection. c Representative images
for transwell invasion assay and wound-healing assays (top: invasion assay; middle: migration assay; bottom: wound healing assay).
d Relative quantitation of cellular invasiveness, migration and wound healing ability in MCF7/C6 cells compared with the wild type
MCF7 cells. e Western blots of E-Cadeherin in MCF7 and MCF7/C6 cells. β-actin was included for equivalent protein loading. Data
represent the average from at least three independent experiments. *Indicates statistical significance (p < 0.05)
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Knocking-down CD44 expression inhibited the aggressive
growth of MCF7/FIR C6 cells
Members of the CD44 family of transmembrane gly-
coproteins, in particularly CD44v6 isoforms, were
shown to be metastatic determinants of tumor cells,
and the expression of several CD44 proteins corre-
lates with aggressive stages of various human cancers.
Thus, CD44 has been considered as a therapeutic
target for metastasizing tumors [38–40]. In CD44-
overexpressed MCF7/C6 cells, siRNA-mediated CD44
inhibition led to a reduction in cell invasiveness and
migration by near 70 % (Fig. 3). The gap filling rates
were also reduced (near 8-folds) by knocking-down of
CD44 in MCF7/C6 cells. These results indicate that
CD44-expressing BCSCs are indeed enriched in the
radioresistant MCF7/C6 population, and CD44 can be
used as an effective therapeutic target to treat radio-
resistant breast cancer.
ATRA induces differentiation and inhibits cancer cell
invasion in MCF-7/C6 cells
ATRA is routinely used as therapeutic agent to induce
differentiation of leukemic stem cells in acute promyelo-
cytic leukemia [41]. ATRA has also been reported to in-
duce differentiation in cancer stem cells, including
BCSCs [42–44]. Given the evidences above showing that
radioresistant MCF7/C6 cells are with enrichment of
CSCs, we thus tested the potential effects of ATRA on
differentiation of MCF7/C6 population. Our results
showed that treatment with 10 μM of ATRA for 72 h
significantly reduced the percentages of cell fractions of
CD44+/CD24-/low-positive (from 28.1 ± 2.38 to 4.27 ±
0.51) and NANOG-positive (from 72.8 ± 4.88 to 50.2 ±
3.79), and slightly reduced the percentage of cells that
were OCT3/4-positive (from 16.6 ± 1.52 to 12.9 ± 2.33).
Exposure to ATRA also increased the expressions of dif-






























































































Fig. 2 Enrichment of BCSCs in MCF7/C6 cells. a Flow cytometry analysis for different stem-cell surface markers in MCF7 and MCF7/C6 cells (left);
b Increased CD44 expression in MCF7/C6 cells comparing to parental MCF7 cells. Top: flow cytometry analysis of CD44 expression; Bottom left:
diagram showing the percentages of cell populations with CD44 expression; Bottom right: Western blot analysis for CD44 protein expression. Data
represent the average from at least three independent experiments. c Diagram (right) showing the changes of the cell fractions with corresponding
positive stem cell markers. d Tumorogenesis of MCF7/C6 cells verses MCF7 cells. Top: images for collected tumors from Tumor initiating test; bottom:
diagram showing the average of tumor volumes. *Indicates statistical significance (p < 0.05)
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in MCF7/C6 cells (Fig. 4a and b, and Additional file 1:
Figure S1B). In addition, cell cycle analysis showed that
ATRA treatment caused increases of S phase in MCF7/
C6 cells after exposure for 24 h when compared to that
of untreated control (from percentage of 21.53 ± 1.63 to
31.26 ± 1.82) or to that of DMSO treatment (from per-
centage of 25.88 ± 2.14 to 31.26 ± 1.82), which support
the concept that that ATRA could induce cell prolifera-
tions in quiescent BCSCs population [47]. As expected,
we also found that ATRA treatment reduced the per-
centages of invasive cells in MCF-7/C6 cells (Fig. 4d and
Additional file 1: Figure S1C).
ATRA enhances sensitivity of MCF7/C6 FIR cells to
radiation treatment
To further evaluate the potential therapeutic impacts of
ATRA on breast cancers cells with acquired radiation re-
sistance, we tested whether ATRA treatment could
change the sensitivities of MCF7/C6 cells to radiation
and chemotherapeutic treatments. For this, we first
examined the direct cytotoxic effect of ATRA on MCF7/
C6 cells and results indicate that treatment with ATRA
at the concentration ranging up to 5 μM induced dose-
dependent inhibition on clonogenic survival (Fig. 5a).
We next examined the effects of ATRA on cellular cap-
ability of DNA damage repair and radiation sensitivity in
MCF7/C6 cells. As shown in Fig. 5b, treatment with
10 μM of ATRA for three days reduced end-joining
activity with statistical significance (from 0.192 ± 0.023
to 0.132 ± 0.018, p = 0.0352). In addition, pretreatment
with ATRA at 10 μM for 72 h sensitized MCF7/C6 cells
to radiation treatment, as determined with clonogenic
survival (from percentage of 77.41 ± 5.30 to 48.54 ± 4.83,
p = 0.0162, (Fig. 5b and c).
ATRA enhances sensitivity of MCF7/C6 cells to
chemotherapy
With clonogenic assays, we also observed that pretreat-
ment with ATRA enhanced clonogenic cell killing effects




























































































































Fig. 3 CD44 inhibition reduced invasiveness, migration and the ability of wound healing in MCF7/C6 cells. a siRNA transfection knocks down
CD44 expression in MCF7/C6 cells. Left: Western blot showing the inhibition of CD44 in MCF7/C6 cells after transfection of siRNA-CD44 for 48 h;
Right: Flow cytometry analysis showing the decrease of cell fractions with CD44-positive expression in MCF7/C6 cells with transfection
of siRNA-CD44. b Representative images for cancer cell invasion, migration and wound-healing assays in MCF7/C6 cells with or without
CD44 inhibition. c Quantitation of invasiveness, migration and wound healing ability in MCF7/C6 cells with CD44 inhibition. Data represent the average
from at least three independent experiments. *Indicates statistical significance (p < 0.05)
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did not affect the clonogenic survival of cells treated
with 1 nM of Doxetaxel (Fig. 6). We further noticed de-
crease of G2/M distribution of cells in epirubincin-
treated MCF7/C6 cells when cells were pretreated with
ATRA, suggesting that the ATRA pretreatment-
enhanced cell killing effect of epirubincin in cells may
occur in G2/M phase of cell cycle.
Discussion
Radioresistance of cancer cells may arise from self-repair
mechanisms (mainly DNA damage repair) or repopula-
tion of radioresistant cancer stem cells, or both [48].
Data presented here indicate that the radioresistant
MCF7/C6 population derived from long-term fraction-
ated doses of radiation is with enrichment of BCSCs and
enhanced capability of NHEJ repair. Compared to paren-
tal MCF7 cells, MCF7/C6 cells are aggressive with in-
creased capacity of invasiveness and migration, and
inhibition of CD44 expression could effectively reduce
cancer cell invasiveness and migration in MCF7/C6 cells.
Most important, our data demonstrated that treatment
with ATRA can induce differentiation of the enriched
BCSCs in MCF7/C6 cell population and sensitized them
to chemotherapeutic agent epirubincin.
More than 60 % cancer patients worldwide use radio-
therapy for the control of tumor growth during the
course of their disease. However, in spite of significant
advancements in tumor imaging and precise of tumor
dose calculation and delivery, the rate of total tumor
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Fig. 4 ATRA induces differentiation of MCF7/C6 cells. a Flow cytometric results for stem-cell surface markers in ATRA-treated MCF7/C6 cells.
MCF7/C6 cells were treated with 1.0 μM of ATRA for 72 h, and were then analyzed by flow cytometry assay. b Westen blots showing that treatment
with 1.0 μM ATRA for 72 h induces expressions of differentiation marker involucrin and Syndecan 3 proteins in MCF7/C6 cells. β-actin was included for
equivalent protein loading. c The effect of ATRA on cell cycle progress in MCF7/C6 cells. Cells were treated with 1.0 μM ATRA, and then analyzed by
flow cytometry. d Representative images showing ATRA treatment reduces the invasiveness of MCF7/C6 cells. Cells were pretreated with 1.0 μM of
ATRA for 72 h, and invasion assay was performed as described in Materials
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Although radiation therapy can decrease the risk of local
cancer recurrence and improves survival, clinical evi-
dence has shown the detrimental effect of treatment
interruptions on tumor control in breast cancer patients
[49]. Interestingly, radiation can also induce a BCSC
phenotype in differentiated breast cancer cells [21, 22],
and CSCs-mediated tumor innate resistance to cytotoxic
agents thus become major clinical challenges towards
the complete eradication of minimal residual disease in
cancer patients [50]. CSCs are also likely to play essen-
tial roles in the metastatic spread of primary tumors
because of their self-renewal capability and their poten-
tial to give rise to differentiated progenies that can adapt
to different target organ microenvironments [51–54].
Preclinical study has suggested differentiation therapy to
be one of the promising strategies for targeting BCSCs
in breast cancer [55]. Thus, targeting these enriched
putative BCSCs in breast cancer cells after sublethal
doses of radiation treatment may have important clinical
impact for breast cancer patients. To this setting, radio-
resistant MCF7/C6 used in this study is a useful experi-
mental model to mimic the radioresistant lesions in the
clinic, especially for the therapy-resistant phenotype of
metastatic tumors. MCF7/C6 cells were derived from
MCF7 cells after fractionized ionizing radiation and are
with developed radiation resistance [16, 19, 56].
Characterization and elucidation of the mechanistic in-
sights and potential therapeutic target to this unique
radioresistant, BCSCs-enriched population which is
highly relevant to the clinic recurrent/metastatic lesions,
will generate informative data for the benefit of breast
cancer patients. Our present work demonstrates the in-
creases of putative CSCs populations in MCF7/C6 cells.
Compared to parental MCF7 cells, MCF7/C6 cells also
exhibited enhanced capabilities for cancer cell invasion
and migration, indicating increased potential for me-
tastasis. Thus, radioresistant MCF7/C6 with BCSCs
enrichment is a useful experimental model to mimic
the radioresistant lesions in the clinic, especially for
the therapy-resistant phenotype of metastatic tumors.
Preclinical study has suggested differentiation therapy
to be one of the promising strategies for targeting
BCSCs in breast cancer [55]. Our data also showed
that inhibition of CD44 expression could effectively
reduce cancer cell invasiveness and migration in MCF7/
C6 cells (Fig. 3).
In this study, we demonstrated the potential thera-
peutic effects of ATRA on MCF7/C6 cells. Retinoids and
its derivatives such as ATRA are promising anti-
neoplastic agents endowed with both therapeutic and
chemo-preventive potential because they are able to
regulate cell growth, differentiation and apoptosis





































































Fig. 5 ATRA exposure increases the sensitivities of MCF7/C6 cells to radiation treatment. a Clonogenic survival of MCF7/C6 cells exposed to ATRA
treatment. Cells were plated and treated with indicated doses of ATRA for 24 h, and cells were then cultured for colony formation. b ATRA exposure
reduces NHEJ activity in MCF 7 FIR cells, and increases radiosensitivity. Cells were co-transfected with control pDsRed and linearized EJ5-GFP plasmid,
and were then treated with 1.0 μM of ATRA for 72 h. in vivo EJ5 activity was measured as described in Materials. Left: in vivo EJ5 assay; Right:
diagram showing the inhibition of EJ5 reunion ability in ATRA-treated cells; c Clonogenic survival assay was performed to determine the changes of
sensitivity in cells treated with 2Gy ionizing radiation. Cells were pretreated with 1.0 μM of ATRA, or DMSO as control, for 72 h, and 500 cells were then
plated and irradiated with 2 Gy of IR. Left: ATRA treatment reduced clonogenic survival of irradiated cells. Right: demonstrative images for colony
survival of irradiated cells. Data represent the average from at least three independent experiments. *Indicates statistical significance (p < 0.05)
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[57–59]. We previously have showed the inhibitory
effects of ATRA on proliferation and cancer cell migra-
tion of breast cancer cells [60]. ATRA has also been re-
cently demonstrated of the ability to induce cancer
stem cell differentiation [42]. We showed here that
ATRA can induce differentiation of enriched BCSCs in
MCF7/C6 cells, and inhibit cancer cell invasiveness/mi-
gration and increase the sensitivities of cells to radi-
ation treatment and to the treatments of epirubincin
and 5-Fu of this cell population. These results thus not
only indicate potential clinic impacts of differentiation
treatment with ATRA as single agent for BCSCs in
therapy-resistant breast cancers, but also suggest ap-
proaches with combination of ATRA and epirubincin,
or other standard-anti-breast cancer chemotherapy,
as novel therapeutic strategy for clinic management
aiming to minimize the risk of recurrent/metastasis,
the major life-threatening tumors in many cancer
patients [61].
Conclusions
Our study suggests a potential clinic impact of ATRA as
a chemotherapeutic agent for treatment of radiation-
resistant breast cancer. The study also provides a
rationale for ATRA as a sensitizer of Epirubincin, a first-
line treatment option for breast cancer patients.
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Fig. 6 ATRA exposure increases the sensitivities of MCF7/C6 cells to chemotherapeutic treatments. a Effect of ATRA on clonogenic survival and
cell cycle distribution in epirubincin-treated MCF7/C6 cells. Cells were pretreated with 1.0 μM ATRA, or DMSO as control, for 72 h, and 500 cells
were then plated and treated with indicated concentrations of Epirubicin. 24 h later, cells were washed with fresh medium and were
then maintained for colony formation assay, or collected for cell cycle analysis. Top left: Survival curve for colony formation; Top right:
demonstrative images for colony survival of epirubincin-treated cells. Bottom: ATRA-induced cell cycle changes in epirubincin-treated cells.
b Effect of ATRA on responses of MCF7/C6 cells to treatments of 5-Fu and Doxetaxel. Cells were pretreated with ATRA as described above, and were
then treated with 1.0 μg/mL of 5-Fu or 0.5 nM of Doxetaxel for 24 h. Colony formation experiments were then performed. Top left: Diagram showing
the change of colony formation in cells exposed to 5-Fu treatment; top right: demonstrative images for colony survival of 5-Fu-treated cells; Bottom
left: Diagram showing the change of colony formation in cells exposed to Doxetaxel treatment; Bottom right: demonstrative images for colony survival
of 5-Fu-treated cells. Data represent the average from at least three independent experiments. *Indicates statistical significance (p < 0.05)
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